Nonoperating Income (Expense) in USD of Seres Therapeutics, Inc. from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Seres Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and change rate from 2013 to Q3 2025.
  • Seres Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $30.7M.
  • Seres Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $109M.
  • Seres Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was -$4.46M, a 190% decline from 2023.
  • Seres Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $4.97M.
  • Seres Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$3.67M, a 238% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

Seres Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $109M $30.7M +$52.5M Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $56.3M $5.03M +$2.35M +87.9% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 $53.9M $59.9M +$58.4M +3803% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 -$4.46M $13.2M +$8.23M +165% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 -$12.7M -$21.9M -$25.4M -712% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $12.8M $2.68M +$5.65M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 $7.11M $1.54M +$2.14M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $4.97M $4.97M +$5.46M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 -$496K $3.57M +$4.47M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$4.96M -$2.97M -$1.56M -111% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$3.4M -$606K +$267K +30.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$3.67M -$489K +$80K +14.1% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-13
Q3 2022 -$3.75M -$895K -$706K -374% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$3.04M -$1.41M -$1.22M -650% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$1.82M -$873K -$734K -528% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$1.09M -$569K -$215K -60.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 -$870K -$189K +$96K +33.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$966K -$188K -$19K -11.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$947K -$139K +$50K +26.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$997K -$354K -$768K -186% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-07
Q3 2020 -$229K -$285K -$1.06M -137% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $830K -$169K -$358K -189% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $1.19M -$189K -$409K -186% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $1.6M $414K +$30K +7.81% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $1.57M $774K +$512K +195% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $1.06M $189K -$160K -45.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-28
Q1 2019 $1.22M $220K -$127K -36.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $1.34M $384K -$438K -53.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-02
Q3 2018 $1.78M $262K -$117K -30.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $1.9M $349K -$49K -12.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $1.95M $347K -$69K -16.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $2.02M $822K +$408K +98.6% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-02
Q3 2017 $1.61M $379K -$28K -6.88% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $1.64M $398K +$171K +75.3% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $1.46M $416K +$204K +96.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $1.26M $414K -$151K -26.7% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-06
Q3 2016 $1.41M $407K +$466K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $945K $227K +$442K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $503K $212K +$427K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $76K $565K Oct 1, 2015 Dec 31, 2015 10-K 2018-03-08
Q3 2015 -$59K +$523K +89.9% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$215K -$156K -264% Apr 1, 2015 Jun 30, 2015 10-Q 2015-08-10
Q1 2015 -$215K Jan 1, 2015 Mar 31, 2015 10-Q 2016-08-11
Q3 2014 -$582K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$59K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10

Seres Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$4.46M -$9.42M -190% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 $4.97M +$8.63M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 -$3.67M -$2.58M -238% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-13
2021 -$1.09M -$88K -8.83% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-05
2020 -$997K -$2.59M -162% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
2019 $1.6M +$255K +19% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $1.34M -$673K -33.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-02
2017 $2.02M +$755K +59.9% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 $1.26M +$1.18M +1558% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-06
2015 $76K +$1.7M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$1.63M -$1.58M -3154% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-16
2013 -$50K Jan 1, 2013 Dec 31, 2013 10-K 2016-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.